The rate of high-grade cervical , vulvar , or vaginal disease related to HPV-@ , @ , @ , @ , and @ in a prespecified per-protocol efficacy population ( susceptible population ) was @ per @ person-years in the @vHPV group and @ per @ person-years in the qHPV group ( efficacy of the @vHPV vaccine , @ % ; @ % confidence interval , @ to @ ) .